Spyre (SYRE) is a biotech company that aims to create the next-generation of inflammatory bowel disease products. CEO Cameron Tuttle joins Oliver Renick to discuss the company as it began trading on the NASDAQ following an acquisition of Aeglea. Tuttle talks about how the IBD market is expected to grow to $29B by 2028, as the CDC estimates that 3.1M Americans have been diagnosed with IBD. Tune in to find out more about the stock market today.
Morning Trade Live
06 Dec 2023
SHARE
The Watch List
02 Feb 2024
Morning Trade Live
29 Feb 2024
The Watch List
05 Mar 2024
Market On Close
01 Mar 2024
Market On Close
30 Jan 2024
Next Gen Investing
25 Apr 2024